Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist/oncologists' practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study.

Abstract:

BACKGROUND:Hematopoietic stem cell transplantation (HSCT) provides a curative therapy for children severely affected by sickle cell disease (SCD). Rejection-free survival after matched sibling donor (MSD) HSCT is very high, but adoption of HSCT as a curative SCD therapy has been slow. In this study, we assess providers' perceptions about MSD HSCT for children with variable SCD severity, and determine the influence of provider characteristics on HSCT referrals. PROCEDURE:After our Institutional Review Board deemed the study exempt, American Society of Pediatric Hematology/Oncology Clinical Forum listserv subscribers and American Society of Hematology members who self-identified as pediatric hematologists/oncologists (PHO) were emailed a survey. Analysis was performed to describe and evaluate correlations between participant demographics (including practice focus within PHO) and likelihood of HSCT referral for each scenario. RESULTS:Spearman's rank correlation analysis did not reveal any significant relationship between demographic characteristics except practice focus and likelihood to refer to HSCT for any scenarios. Providers focused on SCD and HSCT were more likely to refer a child who had never been admitted to the hospital or had suboptimal adherence to hydroxyurea than general PHOs. A significantly higher proportion of all respondents would refer a child with β-thalassemia major (87%) than an asymptomatic child with HbSS (47%, P < .00001) or non-HbSS variant (23%, P < .00001). CONCLUSION:PSCD and HSCT physicians are more likely to refer for MSD HSCT in almost every condition than general PHO practitioners, likely because of increased awareness of long-term effects of SCD and safety of MSD HSCT for children with SCD.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Meier ER,Abraham AA,Ngwube A,Janson IA,Guilcher GMT,Horan J,Kasow KA

doi

10.1002/pbc.28861

subject

Has Abstract

pub_date

2021-03-01 00:00:00

pages

e28861

issue

3

eissn

1545-5009

issn

1545-5017

journal_volume

68

pub_type

杂志文章
  • If only I could turn back time-Regret in bereaved parents.

    abstract:INTRODUCTION:Regret about loss is one of the most intense types of regret experienced in life. Little is known about the bereavement regret of parents whose child has died of cancer. Although knowledge about parents' experiences after their child's death is vital for supporting these families, parents' regret is mostly...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28265

    authors: Sim CW,Heuse S,Weigel D,Kendel F

    更新日期:2020-06-01 00:00:00

  • Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.

    abstract:BACKGROUND:A lack of access to methotrexate levels is common in low- and middle-income countries (LMIC), relevant for 80% of children with cancer worldwide. We evaluated whether high-dose methotrexate (HD-MTX) can be administered safely with extended hydration and leucovorin rescue, with monitoring of serum creatinine ...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.27241

    authors: Vaishnavi K,Bansal D,Trehan A,Jain R,Attri SV

    更新日期:2018-12-01 00:00:00

  • Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.

    abstract:BACKGROUND:The introduction of the United Kingdom Medical Research Council's 10th AML trial (MRC AML 10) protocol incorporating high-dose anthracycline therapy has improved outcome of children with acute myeloid leukemia (AML). In this study, we review the results of childhood AML therapy in a Singapore university hosp...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20834

    authors: Tan RM,Quah TC,Aung L,Liang S,Kirk RC,Yeoh AE

    更新日期:2007-03-01 00:00:00

  • Immunotherapy for osteosarcoma: Where do we go from here?

    abstract::Osteosarcoma is the most common bone tumor in children and young adults, with few advances in survival and treatment, especially for metastatic disease, in the last 30 years. Recently, immunotherapy has begun to show promise in various adult cancers, but the utility of this approach for osteosarcoma remains relatively...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.27227

    authors: Wedekind MF,Wagner LM,Cripe TP

    更新日期:2018-09-01 00:00:00

  • A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.

    abstract:PURPOSE:We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS malignancies. PATIE...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.24541

    authors: Hummel TR,Wagner L,Ahern C,Fouladi M,Reid JM,McGovern RM,Ames MM,Gilbertson RJ,Horton T,Ingle AM,Weigel B,Blaney SM

    更新日期:2013-09-01 00:00:00

  • Mucoepidermoid carcinoma of the parotid gland as a second malignant neoplasm.

    abstract::We report two second malignant neoplasms (SMNs) of the parotid gland. Patient 1 was initially diagnosed with precursor B-cell lymphoblastic lymphoma of the scalp. Eight years after her initial diagnosis she presented with a small, painless mass in the region of her parotid gland. Patient 2 was diagnosed with pre-B-cel...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20306

    authors: Savelli SL,Klopfenstein KJ,Termuhlen AM

    更新日期:2005-12-01 00:00:00

  • Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.

    abstract::Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has n...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26732

    authors: Ding YY,Panzer J,Maris JM,Castañeda A,Gomez-Chiari M,Mora J

    更新日期:2018-01-01 00:00:00

  • High burden of metastases and poor outcome in pelvic PNET.

    abstract::Data on prognostic factors in pelvic PNET are minimal. We analyzed patients with pelvic PNET treated between June 2003 and November 2011 for prognostic factors. Forty-eight (13%) of 374 patients with PNET were pelvic PNET with median age 14.5 years (range: 5-33); 31 (65%) had metastases. After median follow-up of 20.4...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.24552

    authors: Biswas B,Agarwala S,Rastogi S,Khan SA,Mohanti BK,Sharma DN,Pathy S,Bakhshi S

    更新日期:2013-09-01 00:00:00

  • The associations between maternal factors during pregnancy and the risk of childhood acute lymphoblastic leukemia: A meta-analysis.

    abstract:BACKGROUND:Although genetic and environmental factors are considered to be the main causes of acute lymphoblastic leukemia, the associations between maternal factors during pregnancy and the childhood ALL is still unclear. PROCEDURE:In this study, meta-analysis was used. Medline, PubMed, and Web of Science were search...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,meta分析

    doi:10.1002/pbc.25443

    authors: Yan K,Xu X,Liu X,Wang X,Hua S,Wang C,Liu X

    更新日期:2015-07-01 00:00:00

  • Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99).

    abstract:BACKGROUND:Although hematopoietic stem cell transplantation (HSCT) is offered as a curative therapy for pediatric myelodysplastic syndrome (MDS), it may cause severe complications and mortality. Several reports have shown the efficacy of immunosuppressive therapy (IST) in adult patients with refractory anemia (RA), but...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/pbc.22121

    authors: Hasegawa D,Manabe A,Yagasaki H,Ohtsuka Y,Inoue M,Kikuchi A,Ohara A,Tsuchida M,Kojima S,Nakahata T,Japanese Childhood MDS Study Group.

    更新日期:2009-12-01 00:00:00

  • Growth patterns in children with sickle cell anemia during puberty.

    abstract:BACKGROUND:Previous studies of children with homozygous sickle cell anemia (SCA) show impaired growth and maturation. The correlation of this suboptimal growth with metabolic and hematological factors during puberty is poorly understood. PROCEDURE:We studied a group of pre-adolescent children with SCA (19 males, 14 fe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22137

    authors: Rhodes M,Akohoue SA,Shankar SM,Fleming I,Qi An A,Yu C,Acra S,Buchowski MS

    更新日期:2009-10-01 00:00:00

  • The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.

    abstract:BACKGROUND:The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) an...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20813

    authors: Huang L,Lequin M,Pieters R,van den Heuvel-Eibrink MM

    更新日期:2007-04-01 00:00:00

  • Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia.

    abstract:BACKGROUND:The objective of this retrospective study was to assess protection against vaccine preventable diseases (VPDs) in children treated for acute lymphoblastic leukemia (ALL). PROCEDURE:Clinical characteristics and vaccination records were collected. Antibodies against VPDs were measured after completion of chem...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26187

    authors: de de la Fuente Garcia I,Coïc L,Leclerc JM,Laverdière C,Rousseau C,Ovetchkine P,Tapiéro B

    更新日期:2017-02-01 00:00:00

  • Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis.

    abstract:BACKGROUND:Hemophagocytic Lymphohistiocytosis (HLH) is characterized by uncontrolled inflammation that is generally fatal without immune modulating chemotherapy. At Texas Children's Hospital, we have observed significant central nervous system (CNS) toxicity in several patients treated for HLH according to the Histiocy...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21838

    authors: Thompson PA,Allen CE,Horton T,Jones JY,Vinks AA,McClain KL

    更新日期:2009-05-01 00:00:00

  • A novel mutation of ABCG5 gene in a Turkish boy with phytosterolemia presenting with macrotrombocytopenia and stomatocytosis.

    abstract::Phytosterolemia is a rare autosomal recessive sterol storage disease caused by mutations in ABCG5 and ABCG8 genes. A 9-year-old Turkish boy who was presented with exclusively hematologic abnormalities had elevated plant sterol levels. Sequencing of ABCG5 and ABCG8 genes revealed a novel homozygous IVS10-1 G>T mutation...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24934

    authors: Kaya Z,Niu DM,Yorulmaz A,Tekin A,Gürsel T

    更新日期:2014-08-01 00:00:00

  • Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.

    abstract::To assess safety and tolerability, we administered valacyclovir, an oral anti-viral medication that inhibits erythrocyte sickling in vitro, to 14 subjects with sickle-cell anemia for 1 week at a standard dose of 1,000 mg every 8 hr. No clinically significant adverse effects occurred. In 11 subjects in steady state, th...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22809

    authors: Ender KL,DeBellis RH,Erlanger BF,Billote GB,Brittenham GM

    更新日期:2011-05-01 00:00:00

  • Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation.

    abstract:BACKGROUND:The purpose of this study was to determine the prevalence of pulmonary dysfunction in pediatric hematopoietic cell transplant (HCT) survivors and to identify associated risk factors. PROCEDURE:In a cross-sectional study, patients surviving at least 5 years after pediatric HCT were requested to undergo pulmo...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20531

    authors: Hoffmeister PA,Madtes DK,Storer BE,Sanders JE

    更新日期:2006-10-15 00:00:00

  • Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma.

    abstract:BACKGROUND:Positron emission tomography (PET) and gallium scans facilitate diagnosis and staging, evaluation of response to therapy, and monitoring for relapse in Hodgkin lymphoma (HL), but have not been compared in pediatric HL. PROCEDURE:We performed concurrent PET and gallium scans on 44 pediatric HL patients at di...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21574

    authors: Hines-Thomas M,Kaste SC,Hudson MM,Howard SC,Liu WA,Wu J,Kun LE,Shulkin BL,Krasin MJ,Metzger ML

    更新日期:2008-08-01 00:00:00

  • Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

    abstract:BACKGROUND:M6620 is a novel inhibitor of the DNA damage repair enzyme ATR, and has potentiated the activity of cisplatin and irinotecan in non-small cell lung cancer and colon cancer xenografts, respectively. PROCEDURES:M6620 was tested in vitro at concentrations ranging from 1.0 nM to 10.0 μM and at 75 nM in combinat...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26825

    authors: Kurmasheva RT,Kurmashev D,Reynolds CP,Kang M,Wu J,Houghton PJ,Smith MA

    更新日期:2018-02-01 00:00:00

  • Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry.

    abstract:BACKGROUND:Males have a higher incidence of medulloblastoma (MB) than females, but the effect of gender on survival is unclear. Studies have yielded conflicting results, possibly due to small sample sizes or differences in how researchers defined MB. We aimed to determine the effect of gender on survival in MB using a ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21832

    authors: Curran EK,Sainani KL,Le GM,Propp JM,Fisher PG

    更新日期:2009-01-01 00:00:00

  • Contributing factors and outcomes of treatment refusal in pediatric oncology in Germany.

    abstract:BACKGROUND:In Germany, about 1,800 new cases of pediatric cancer under 15 years of age are diagnosed each year and survival rates approach 80%. Although treatment is covered by health insurance and is thus available for all patients at no cost, treatment refusal and treatment discontinuation have been observed. However...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26111

    authors: Zuzak TJ,Kameda G,Schütze T,Kaatsch P,Seifert G,Bailey R,Längler A

    更新日期:2016-10-01 00:00:00

  • The involvement of primary care physicians in care for childhood cancer survivors.

    abstract:BACKGROUND:Childhood cancer survivors (CCS) are at risk of developing long-term morbidity, which is likely to be presented to a primary care physician (PCP). Therefore, insight into CCS's PCP-based health care use is needed. We investigated the volume and underlying health problems of PCP-based health care use and the ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27774

    authors: Streefkerk N,Heins MJ,Teepen JC,Feijen EAM,Bresters D,van Dulmen-den Broeder E,van der Heiden-van der Loo M,van den Heuvel-Eibrink MM,van Leeuwen FE,Loonen JJ,van der Pal HJH,Ronckers CM,Versluys AB,Tissing WJE,Korevaar JC,

    更新日期:2019-08-01 00:00:00

  • Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults.

    abstract:BACKGROUND:Childhood cancer is relatively rare and tends to present specific age distribution, as a prognostic factor for some of these diseases. Information on how young age affects prognosis, response to chemotherapy, and local control options in children versus AYA with osteosarcoma (OST) is minimal. METHODS:In ord...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25459

    authors: Eleutério SJ,Senerchia AA,Almeida MT,Da Costa CM,Lustosa D,Calheiros LM,Barreto JH,Brunetto AL,Macedo CR,Petrilli AS

    更新日期:2015-07-01 00:00:00

  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

    abstract:BACKGROUND:SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. PROCEDURES:SCH 727965 was tested against the PPTP in vitro panel using 96 hours exposure at concentra...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24073

    authors: Gorlick R,Kolb EA,Houghton PJ,Morton CL,Neale G,Keir ST,Carol H,Lock R,Phelps D,Kang MH,Reynolds CP,Maris JM,Billups C,Smith MA

    更新日期:2012-12-15 00:00:00

  • Long-term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan.

    abstract:BACKGROUND:Juvenile xanthogranuloma (JXG) is the most common non-Langerhans cell histiocytosis in children. The mortality and morbidity of JXG with extracutaneous lesions remain unclear. METHODS:Data of patients aged < 18 years who were diagnosed with JXG between 2001 and 2010 were retrospectively collected through a ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28381

    authors: Maeda M,Morimoto A,Shioda Y,Asano T,Koga Y,Nakazawa Y,Kanegane H,Kudo K,Ohga S,Ishii E,Histiocytosis Study Group of the Japanese Society of Pediatric Hematology\/Oncology.

    更新日期:2020-07-01 00:00:00

  • APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.

    abstract:BACKGROUND:MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) are effective therapies for Hodgkin disease (HD) that may cause long-term toxicities in children. APE (cytosine arabinoside, cisplatin, etoposide) is a non-cross-resistant regimen wit...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20563

    authors: Wimmer RS,Chauvenet AR,London WB,Villaluna D,de Alarcon PA,Schwartz CL

    更新日期:2006-03-01 00:00:00

  • Multidisciplinary management of endocrinopathies and treatment-related toxicities in patients with Bloom syndrome and cancer.

    abstract::The treatment of malignancy in cancer predisposition syndromes that also confer exquisite sensitivity to standard chemotherapy and radiation regimens remains a challenge. Bloom syndrome is one such disorder that is caused by a defect in DNA repair, predisposing to the development of early-onset age-related medical con...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28815

    authors: Fein Levy C,Presswala LS,Slomovic A,Stiefel J,Schulman-Rosenbaum R

    更新日期:2021-02-01 00:00:00

  • Renal function after hematopoietic stem cell transplantation in children.

    abstract:OBJECTIVES:The aim of this study was to assess glomerular and tubular renal function after HSCT in children in a prospective trial. METHODS:Renal function was assessed prospectively before HSCT (on day -10), on days +30, +100, and at least 6 months after transplantation in 34 patients (21 females/13 males) with a mean...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22030

    authors: Hazar V,Gungor O,Guven AG,Aydin F,Akbas H,Gungor F,Tezcan G,Akman S,Yesilipek A

    更新日期:2009-08-01 00:00:00

  • Pulmonary function abnormalities in children treated with whole lung irradiation.

    abstract:BACKGROUND:We sought to determine the prevalence of abnormal pulmonary function tests (PFTs) in a cohort of children who had received whole lung irradiation (WLI) for treatment of metastatic disease. PROCEDURE:This was a retrospective (1988-2003) chart review that included all children treated at our institution with ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20457

    authors: Weiner DJ,Maity A,Carlson CA,Ginsberg JP

    更新日期:2006-02-01 00:00:00

  • Adolescent and young adult oncology: transition of care.

    abstract::The fundamental purposes underlying formal health care transition from the pediatric to adult setting for young adult survivors of childhood cancer are to facilitate the continuous, medically and developmentally appropriate implementation of risk-based guidelines for the monitoring and management of late effects of ch...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.21455

    authors: Freyer DR,Brugieres L

    更新日期:2008-05-01 00:00:00